Sunday, 24 August 2008

Fewer teenage girls report having sex: StatsCan

The number of Canadian teenagers world Health Organization say they've had sexual intercourse at least one time is on the refuse, Statistics Canada reported Wednesday.


In 2005, 43 per cent of teens aged 15 to 19 reported that they had sexual social intercourse at least once, mastered from 47 per cent in 1996-1997.


The decline occurred due to young women. For them, the proportion who reported having had intercourse reduced from 51 per cent in 1996 to 43 per centime in 2005. Among young men, the proportion stayed unchanged at 43 per cent.


"As well, the symmetry who reported becoming sexually active at a identical early eld decreased," wrote Michelle Rotermann of Statistics Canada's health information and research sectionalization in Ottawa.


"However, among those who were sexually active, there was no meaning change in the likelihood of having multiple partners or, for males, victimization condoms. So while some adolescents have adopted measures to reduce their risks of sexually transmitted contagion and unwanted pregnancy, others report speculative behaviour."


Throughout the study period, the per centum of teens reporting intercourse was higher at old ages. About two-thirds of those aged 18 or 19 had had carnal knowledge, compared with about tierce of those aged 15 to 17.

Condom use fades with age

Between 2003 and 2005, the proportion of sexually active teenaged girls wHO reported victimization a prophylactic rose from 65 per cent to 70 per cent. Among teenage boys, the ratio stayed about 80 per cent.





'Information wish this is very of import when design education curiculums and trying to pinpoint specific problems within a given demographic.'


�Phipps



Add your commentary






More information

Thursday, 14 August 2008

Peregrine Pharmaceuticals Doses First Patient In Phase II Trial Of Bavituximab In Patients With Advanced Breast Cancer

�Peregrine
Pharmaceuticals, Inc. (Nasdaq: PPHM) proclaimed that affected role screening
and dosing has begun in a Phase II trial designed to evaluate the safety
and efficacy of bavituximab in combination with chemotherapy in patients
with advanced chest cancer. The new trial run is the second Phase II study
evaluating bavituximab in advanced breast cancer patients, and Peregrine
too is conducting a third base Phase II combination therapy trial of
bavituximab in non-small cell lung cancer the Crab (NSCLC) patients. The principal
objective of the newfangled breast cancer the Crab study is to appraise the boilers suit tumor
response rate to the combination of bavituximab with carboplatin and
paclitaxel.



"The combination of bavituximab with the chemotherapy drugs carboplatin
and paclitaxel performed well in an earlier Phase I study, and we look
forward to learning more about bavituximab's potential in this larger
breast cancer study," said Steven W. King, chair and CEO of Peregrine.
"With trey Phase II studies now underway, we look forrard to significant
clinical data being generated throughout the rest of this year."



In the trial's two-stage design, up to 15 patients with advanced breast
cancer will be enrolled initially. The study volition then be expanded up to a
total of 46 patients if promising results are observed. Secondary
objectives of the trial include measure time to tumor patterned advance,
duration of response, boilers suit patient selection and rubber parameters. Tumor
response will be evaluated using Response Evaluation Criteria in Solid
Tumors (RECIST) parameters. Patients may continue to receive bavituximab
unequaled after completion of chemotherapy as long as the cancer does not
procession and side effects are acceptable. The trial is being conducted in
India according to International Conference on Harmonization (ICH) and Good
Clinical Practices (GCP) standards.



Peregrine recently reported that a Phase II trial assessing the
combination of bavituximab and docetaxel in patients with metastatic breast
cancer had achieved the pre-specified Stage A primary endpoint needed to
expand the trial to the second stage. Seven of the 14 evaluable patients
achieved partial neoplasm responses and seven had stable disease at week eight
according to RECIST criteria.



"Bavituximab showed bright signs of anti-tumor action in
metastatic breast cancer patients in combination with chemotherapy in a
clinical study we helped impart last class," said Dr. Raghunadharao
Digumarti, professor of medical oncology at the Nizams Institute of Medical
Sciences in Hyderabad, India and a principal investigator of the
bavituximab Phase II breast cancer test. "We seem forward to assessing the
results from this test in a larger population of patients with boob
cancer, the most unremarkably diagnosed cancer in women worldwide."



According to the World Health Organization, white meat cancer is the most
commonly diagnosed cancer in women, and is second only to lung crab as a
leading cause of female cancer deaths. The National Cancer Institute
estimates that approximately 182,460 U.S. women will be diagnosed with
white meat cancer in 2008 and 40,480 women will die of the disease.



Bavituximab is a monoclonal antibody antibody that binds to the cellular
membrane constituent phosphatidylserine (PS) that is usually located inside
cells, but which becomes exposed on the outside of the cells that line the
stock vessels of tumors, creating a specific target for anti-cancer
treatments. By binding to PS, bavituximab is believed to help circulate the
body's immune arrangement to demolish the tumor and the tumor rip vessels.
Bavituximab currently is in 2 separate Phase II combination therapy
trials for the treatment of advanced tit cancer and a Phase II
combination therapy trial for the treatment of non-small cell lung genus Cancer.
Peregrine of late reported that a Phase II run assessing the combination
of bavituximab and docetaxel in patients with metastatic breast cancer had
achieved the pre-specified Stage A master efficacy termination needed to
expand the trial to the second stage. A Phase I bavituximab monotherapy
trial in advanced firm cancers is also continuing.

About Peregrine Pharmaceuticals



Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a
portfolio of advanced product candidates in clinical trials for the
handling of cancer and hepatitis C computer virus (HCV) infection. The company is
pursuing three separate clinical programs in cancer and HCV infection with
its lead product candidates bavituximab and Cotara(R). Peregrine also has
in-house manufacture capabilities through and through its altogether owned underling
Avid Bioservices, Inc. (hypertext transfer protocol://www.avidbio.com), which provides developing
and bio-manufacturing services for both Peregrine and remote customers.
Additional information about Peregrine pot be found at
hypertext transfer protocol://www.peregrineinc.com.



Safe Harbor Statement: Statements in this push release which are non
purely diachronic, including statements regarding Peregrine
Pharmaceuticals' intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future ar forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. The forward-looking statements involve risks and uncertainties
including, but not limited to, the risk that the company will experience
delays or difficulties in enrolling patients in the study, the risk of infection that
the standard carboplatin and paclitaxel response rate will not be improved
as a result of the combination therapy, and the peril that the results from
this trial will not be consistent with the results of prior trials or
preclinical studies. It is important to note that the company's existent
results could differ materially from those in whatever such modern
statements. Factors that could cause actual results to differ materially
include, merely are non limited to, uncertainties associated with completing
preclinical and clinical trials for our technologies; the early stage of
merchandise development; the significant costs to rise our products as all
of our products are currently in development, presymptomatic studies or
clinical trials; obtaining extra financing to support our operations
and the development of our products; obtaining regulatory approval for our
technologies; hoped-for timing of regulatory filings and the potential
success in gaining regulatory favourable reception and complying with governmental
regulations applicable to our business. Our business could be affected by a
number of other factors, including the risk factors listed from time to
time in the company's SEC reports including, but not limited to, the annual
report on Form 10-K for the year ended April 30, 2008. The company cautions
investors not to place undue reliance on the advanced statements
contained in this press handout. Peregrine Pharmaceuticals, Inc. disclaims
any obligation, and does not undertake to update or revise any
forward-looking statements in this exhort release.


Peregrine Pharmaceuticals, Inc.
http://www.peregrineinc.com



More info

Wednesday, 6 August 2008

Respiratory Symptoms Among Bakers' Apprentices: Are There Mechanisms Other Than Allergy?

�It has previously been claimed that working as a baker involves, as a
consequence, a great risk of evolving allergy and respiratory symptoms.
The basis for this assumption was based on cross-section studies.




In this subject field, undertaken by Tina Skjodt (Aarhus University Hospital,
Aarhus, Denmark) and her team, bakers' apprentices were followed
prospectively for three years to make up one's mind the sequence by which
allergy, asthma and hypersensitised rhinitis evolved.
An extensive panel of common and occupational allergens was used for
steady testing.




Surprisingly, only a few bakers' apprentices became sensitised to
occupational allergens, whereas the occurrence of new respiratory
symptoms was high. The development of new symptoms was associated
with the duration of exposure.
Thus, the study points toward mechanisms other than allergy as being
responsible for respiratory symptoms among bakers' apprentices.



Title of Original Article

The incidence of respiratory symptoms and sensitisation in baker apprentices

European Respiratory Journal (Erj), Vol. 32, No 2




The European Respiratory Journal is the peer-reviewed scientific
publication of the European Respiratory Society (more than 8,000
specialists in lung diseases and respiratory medicine in Europe, the
United States and Australia).



European Respiratory Journal



More info

Friday, 27 June 2008

Pendragon

Pendragon   
Artist: Pendragon

   Genre(s): 
Rock
   



Discography:


The World   
 The World

   Year: 2002   
Tracks: 8


Acoustically Challenged   
 Acoustically Challenged

   Year: 2002   
Tracks: 10


The Round Table   
 The Round Table

   Year: 2001   
Tracks: 8


Not Of This World   
 Not Of This World

   Year: 2001   
Tracks: 12


The Masquerade Overture   
 The Masquerade Overture

   Year: 1996   
Tracks: 8


Fallen Dreams and Angels   
 Fallen Dreams and Angels

   Year: 1994   
Tracks: 4


The Window Of Life   
 The Window Of Life

   Year: 1993   
Tracks: 6


Kowtow   
 Kowtow

   Year: 1988   
Tracks: 9


Believe   
 Believe

   Year:    
Tracks: 9




Neo-prog isthmus Pendragon formed in London during the judicious years of tinder, just didn't combine until 1983, when the banding began playing round London and earned a little bit at that year's Reading Festival. The lineup stabilised, after the 1985 album Gem, around vocalist/guitarist Nick Barrett, bassist Peter Gee, drummer Fudge Smith and keyboard participant Clive Nolan. Pendragon recorded the live album 9:15 in 1986 and began to plant a continental fan base the following twelvemonth. European audiences proved enthusiastic, spawning a undertake with the French M.S.I. tag; however, the grouping was forced to physical body its possess Toff tag precisely to spill material in England.


Pendragon pose inactive through the rest of the '80s, just returned in 1991 with The Rest of Pendragon -- a reissue of the early Fly High, Fall Far with added B-sides -- and their first base unexampled album in five years, The World. The album earned a U.S. handout in 1993, followed by The Window of Life. A deal with the Japanese Pony Canyon tag in 1994 resulted in the reissue of the integral back catalogue, in plus to the novel Fallen Dreams and Angels. The isthmus made its U.S. debut a year afterward at L.A.'s Progfest, and released The Masquerade Overture early the next year.






Thursday, 19 June 2008

Macpherson's Bedroom Behaviour Revealed In New Tell-all Book

Supermodel Elle Macpherson's encouraging bedroom behaviour is set to be revealed in a new tell-all book. Former Calvin Klein model Bruce Hulse recalls his sexual encounters with MacPherson in his upcoming bed-hopping memoir Sex, Love and Fashion, scheduled for release in August . Hulse, now married with two children, reveals a steamy hook-up with the model at the peak of his career could have turned sour if the beauty hadn't been so understanding. The 55-year-old recounts his lacklustre performance in the bedroom with the Aussie stunner, who he says "stripped down in front of me", before he lost his sex drive. But according to Hulse, MacPherson wasn't upset by his inability to perform, choosing instead to propose a platonic relationship. Hulse recalls of MacPherson's response, "No worries, Bruce... Let's just be friends, then," before claiming the pair later hooked-up for one more steamy session under his parents' roof. The book also details his exploits with beauties Paulina Porizkova, Anie MaCDowell and Tatjana Patitz.


See Also

Thursday, 12 June 2008

Amy Winehouse to attempt “hardcore rehab” with Israeli doctor

Amy WinehouseTroubled Amy Winehouse is reportedly set to to attempt “hardcore rehab” with controversial Israeli Doctor, Andre Waismann, who has been dubbed ‘Dr Wash’ for his clean-up skills.


The singer, 24, has been persuaded to see Waismann, whose unconventional method — pumping his patients with a drug which blocks the brain’s craving for cocaine so they have no withdrawal symptoms when conscious — takes as little as four hours.


He claims to have helped 3,000 heroin junkies nail their addiction with his swift but controversial treatment. And has insisted: “I can cure her.”


It was claimed earlier this week that the Rehab singer was planning to fly to Israel to see the doctor, but Amy’s parents, Janis and Mitch, have confirmed they are fixing an appointment with Waismann to visit the star in England over the next couple of weeks.




See Also

Friday, 6 June 2008

Vanity Fair cancels Tinseltown Oscar night

Vanity Fair has cancelled its annual Academy Awards party on 24 February even though the writers guild is said to be on track for a possible deal with studios.
A statement posted on VanityFair.com said: "After much consideration, and in support of the writers and everyone else affected by this strike, we have decided that this is not the appropriate year to hold our annual Oscar party."
The magazine added: "We want to congratulate all of this year's nominees and we look forward to hosting our 15th Oscar party next year."
The annual post-Oscar soiree often lures more luminaries than the ceremony itself and the event has been a fixture for partygoers since its inception in 1994.
The night's big winners and nominees typically turn out, along with A-listers including Angelina Jolie, Brad Pitt, Oprah Winfrey, Jack Nicholson, Madonna, Cher, Sean Penn, Joni Mitchell and Al Gore, who have attended the party in previous years.
Vanity Fair editor Graydon Carter decided to cancel the party because even if the three-month writers strike was resolved before the Academy Awards, its effect on Tinseltown was likely to linger.
In a statement Carter said: "Inasmuch as Vanity Fair is a collection of writers, photographers and artists, we do feel ourselves in aligned solidarity with the writers, directors and actors in the film business."
A year after holding its first Oscar party, Vanity Fair introduced its annual Hollywood issue. This year's issue, featuring 10 young actresses on its tri-fold cover, reaches newsstands next week.